FS KKR Capital Mounts a $450M Defense as Revenue Plunges and Institutions Pile In

Parent KKR injects $150M in convertible preferred, $300M buyback, and fee waiver to stabilize BDC after revenue miss and dividend cut; shares trade at $9.26 with litigation overhang.

The clearest signal that FS KKR Capital is navigating troubled waters may not be the 28% year-to-date share-price slump or the 24% drop in first-quarter revenue. It’s the scope of the countermeasures: a $150 million convertible preferred investment from its parent, a $300 million buyback authorization, a $150 million tender offer, and a rare fee waiver from management. Combined, the package totals roughly $450 million in support for a business development company that reported a net loss of $2.00 per share and a net asset value of $18.83 per unit.

Revenue for the three months ended March came in at $304 million, well below analyst estimates. Net investment income per share of $0.41 also missed forecasts, underscoring the operational headwinds. The shares now trade near $9.26, far under their 200-day moving average of about $12, while the dividend has been trimmed to $0.42 a quarter — a six-cent reduction from the prior payout, equating to a yield of roughly 15%.

The parent company, KKR, is injecting cash through a KKR subsidiary that is buying $150 million in convertible preferred shares. These securities carry a 5% cash coupon or a 7% payment-in-kind alternative. At the same time, management is halving its incentive fees for the next four quarters, providing a direct boost to distributable earnings. On the buyback front, the board has authorized a $300 million open-market repurchase program. That sits alongside a separate $150 million tender offer at $11.00 per share, a premium of nearly 19% to the current price, which runs through mid-June.

Yet while the sponsor mounts a defense, a different class of investor is charging in. World Investment Advisors increased its stake by nearly 440% in the first quarter, a move that dwarfs the more modest accumulations from Goldman Sachs (up about 14%) and Rothschild Investment (up around 60%). Insider activity also turned bullish: board member Daniel Pietrzak picked up 5,000 shares in late February. The buying suggests that some deep-pocketed players see value despite the earnings deterioration.

A cloud of litigation adds to the uncertainty. A class-action lawsuit alleging securities fraud covers the period from May 2024 through February 2026, creating a legal overhang that will take months to resolve. On the Street, analysts remain cautious. The consensus rating is “reduce,” with a price target of $10.58. Keefe, Bruyette & Woods is only slightly more optimistic, assigning a “market perform” and an $11 target — matching the tender price.

For income-focused investors, the dividend remains the anchor. The next payment of $0.42 per share goes to holders of record on June 17, 2026, and is due in early July. With the sponsor’s cash injection, the buyback programs, and the fee waiver all designed to stem the slide, the stock is a high-risk bet on a turnaround — one that institutions, and the parent itself, are willing to place.